Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

Journal of Antimicrobial Chemotherapy

Volumn 52, Issue 5, 2003, Pages 790-795

  Zhang, Ying ^a   Wade, Mary Margaret ^a   Scorpio, Angelo ^b   Zhang, Hao ^a   Sun, Zhonghe ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

M. tuberculosis; Mechanism of action; Membrane potential; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; AZIDE; BACTERIAL PROTEIN; BACTERIAL RNA; DICYCLOHEXYLCARBODIIMIDE; PYRAZINAMIDE; PYRAZINOIC ACID; ROTENONE; TUBERCULOSTATIC AGENT;

ACIDITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS; BACTERIAL REPRODUCTION; CELL ENERGY; CELL FUNCTION; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; MEMBRANE POTENTIAL; MEMBRANE TRANSPORT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PH;

ANTITUBERCULAR AGENTS; AZIDES; DICYCLOHEXYLCARBODIIMIDE; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIALS; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; ROTENONE;

EID: 0242437861     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg446     Document Type: Article

References (31)

1. East African/British Medical Research Council. (1976). American Review of Respiratory Disease 114, 471-5.
2. Hong Kong Chest Service/British Medical Research Council. (1979). Tubercle 60, 201-10.
3. Singapore Tuberculosis Service/British Medical Research Council. (1981). Tubercle 162, 95-102.
4. British Thoracic Association. (1982). American Review of Respiratory Disease 126, 460-2.
5. Mitchison, D. A. (1985). The action of antituberculosis drugs in short course chemotherapy. Tubercle 66, 219-25.
6. Zhang, Y. & Mitchison, D. A. (2003). The curious characteristics of pyrazinamide: a review. International Journal of Tuberculosis and Lung Disease 7, 6-21.
7. McCune, R. M., Tompsett, R. & McDermott, W. (1956). The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by administration of pyrazinamide and a companion drug. Journal of Experimental Medicine 104, 763-802.
8. Grosset, J. (1978). The sterilizing value of rifampicin and pyrazinamide in experimental short course chemotherapy. Tubercle 59, 287-97.
9. Tarshis, M. S. & Weed, W. A. (1953). Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. American Review of Tuberculosis 67, 391-5.
10. McDermott, W. & Tompsett, R. (1954). Activation of pyrazinamide and nicotinamide in acidic environment in vitro. American Review of Tuberculosis 70, 748-54.
11. Salfinger, M. & Heifets, L. B. (1988). Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrobial Agents and Chemotherapy 32, 1002-4.
12. Zhang, Y., Permar, S. & Sun, Z. (2002). Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. Journal of Medical Microbiology 51, 42-9.
13. Heifets, L. B. & Lindholm-Levy, P. J. (1990). Is pyrazinamide bactericidal against Mycobacterium tuberculosis.? American Review of Respiratory Disease 141, 250-2.
14. Zhang, Y., Scorpio, A., Nikaido, H. et al. (1999). Role of acid pH and deficient efflux of pyrazinoic acid in the unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. Journal of Bacteriology 181, 2044-9.
15. Yeager, R. L. Munroe, W. G. & Dessau, F. I. (1952). Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. American Review of Tuberculosis 65, 523-34.
16. Konno, K., Feldman, F. M. & McDermott, W. (1967). Pyrazinamide susceptibility and amidase activity of tubercle bacilli. American Review of Respiratory Disease 95, 461-9.
17. Scorpio, A. & Zhang, Y. (1996). Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Medicine 2, 662-7.
18. Zimhony, O., Cox, J. S., Welch, J. T. et al. (2000). Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FAS-I) of Mycobacterium tuberculosis. Nature Medicine 6, 1043-7.
19. Boshoff, H. I., Mizrahi, V. & Barry, C. E., III (2002). Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I. Journal of Bacteriology 184, 2167-72.
20. Zhang, Y. & Telenti, A. (2000). Genetics of drug resistance in Mycobacterium tuberculosis. In Molecular Genetics of Mycobacteria (Hatfull, G. F. & Jacobs, W. R., Jr, Eds), pp. 235-54. ASM Press, Washington, DC, USA.
21. Zhang, Y., Zhang, H. & Sun, Z. (2003). Susceptibility of Mycobacterium tuberculosis to weak acids. Journal of Antimicrobial Chemotherapy 52, 56-60.
22. Freese, E., Sheu, C. & Gallier, E. (1973). Function of lipophilic acids as antimicrobial food additives. Nature 241, 321-5.
23. + concentration in Bacillus subtilis as determined by an ion-selective electrode. Biochimica et Biophysica Acta 600, 844-52.
24. Azzi, A., Casey, R. P. & Nalecz, M. J. (1984). The effect of N,N′-dicyclohexylcarbodiimide on enzymes of bioenergetic relevance. Biochimica et Biophysica Acta 768, 209-26.
25. Bois, R. & Estabrook, R. W. (1969). Nonheme iron protein as a possible site of rotenone inhibition of mitochondrial NADH dehydrogenase. Archives of Biochemistry and Biophysics 129, 362-9.
26. Verkhovsky, M. I., Jasaitis, A., Verkhovskaya, M. L. et al. (1999). Proton translocation by cytochrome c oxidase. Nature 400, 480-3.
27. Moat, A. G. and Foster, J. W. (1995). Microbial Physiology, 3rd edn. Wiley-Liss, New York, NY, USA.
28. Kaim, G. & Dimroth, P. (1998). ATP synthesis by the F1Fo ATP synthase of Escherichia coli is obligatorily dependent on the electric potential. FEBS Letters 434, 57-60.
29. Executive Summary of the Scientific Blueprint for TB Drug Development. (2001). Tuberculosis (Edinb) 81, Suppl. 1, 1-52.
30. Coates, A., Hu, Y., Bax, R. et al. (2002). The future challenges facing the development of new antimicrobial drugs. Nature Reviews Drug Discovery 1, 895-910.
31. Zhang, Y. & Amzel, L. M. (2002). Tuberculosis drug targets. Current Drug Targets 3, 131-54.